Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 3 1Phase 1/2 1

Status

Unknown 5Active not recruiting 1

Sponsor Class

OTHER 9INDUSTRY 6NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Plasma cell 1Gastrointestinal 1

Conditions

Leukemia 2Plasmacytoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × CF regimen × Clear all
NCT04550260 2026-05-13

KUNLUN

AstraZeneca

Phase 3 Active not recruiting
640 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04632316 2022-06-21

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Glycostem Therapeutics BV

Phase 1/2 Unknown
33 enrolled
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04665063 2020-12-29

A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
20 enrolled
Lymphoid

Hodgkin Disease

NCT04666168 2020-12-14

A Multicenter Clinical Study on the Safety and Efficacy of CAR-T in the Treatment of Relapsed / Refractory Non Hodgkin's Lymphoma

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
200 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT04665076 2020-12-11

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
60 enrolled
Plasma cell

Plasmacytoma

NCT04610125 2020-10-30

Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children

Hebei Senlang Biotechnology Inc., Ltd.

Phase NA Unknown
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡